Inventor · disambiguated record
Annie Yang Weaver
Also filed as: WEAVER ANNIE YANG
7 granted patents·9 pending applications·128 citations·filing 2014–2023
87Inventor score
Top patents by PatentIndex Score
16 records- 0198US10179817B2Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Jan 15, 2019·36 cites·58 claims
- 0297US10745481B2Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Aug 18, 2020·22 cites·88 claims
- 0395US11753466B2Anti-CD166 antibodies, activatable anti-CD166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Granted Sep 12, 2023·7 cites·64 claims
- 0495US10233244B2Anti-ITGA3 antibodies, activatable anti-ITGA3 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2016·Granted Mar 19, 2019·26 cites·48 claims
- 0595US9737623B2Antibodies that bind activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2014·Granted Aug 22, 2017·19 cites·21 claims
- 0694US11267896B2Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Granted Mar 8, 2022·10 cites·34 claims
- 0793US10568977B2Antibodies that bind activatable antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2017·Granted Feb 25, 2020·8 cites·20 claims
- 0878US2024076374A1Anti-cd166 antibodies, activatable anti-cd166 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2023·Application pending·0 cites
- 0972US2022306759A1Anti-cd71 antibodies, activatable anti-cd71 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2022·Application pending·0 cites
- 1057US2024115703A1Genetically engineered anti-cd19 car-t cells for use in treating b-cell malignanciesCRISPR THERAPEUTICS AG·Filed 2023·Application pending·0 cites
- 1156US2022202859A1Cancer treatment using cd38 inhibitor and/or lenalidomide and t-cells expressing a chimeric antigen receptorCRISPR THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 1252US2019117789A1Activatable anti-cd166 antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2018·Application pending·0 cites
- 1352US2021100913A1Activatable anti-cd166 antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2020·Application pending·0 cites
- 1452US2019309072A1Anti-itga3 antibodies, activatable anti-itga3 antibodies, and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
- 1551US2023220059A1Genetically engineered t cells expressing bcma-specific chimeric antigen receptors and uses thereof in cancer therapyCRISPR THERAPEUTICS AG·Filed 2021·Application pending·0 cites
- 1646US2022023439A1Activatable anti-cd166 antibodies and methods of use thereofCYTOMX THERAPEUTICS INC·Filed 2019·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Annie Yang Weaver files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →